Research-use peptides are advertised at prices below any prescription option, often under $60 a month. That is true, and it is the honest place to start. What the advertised price does not include is a prescriber deciding the dose, a licensed pharmacy preparing the vial, or anyone accountable if it is wrong. This article compares the three categories people actually weigh: an FDA-approved brand-name medication, a compounded medication, which is not FDA-approved, prescribed by a licensed provider, and a research-use peptide sold with no prescription. Forva offers the first two, on separate terms. It does not offer the third, which by definition has no licensed provider in it.
If you came here for the lowest legitimate price at Forva, it is $139 every 4 weeks, about $151 per calendar month, on a 48-week compounded semaglutide plan with $1,668 charged at checkout, if a licensed provider prescribes it. Compounded medication is not FDA-approved. The rest of this article is what that difference in price actually buys.
What is the gray market for GLP-1 peptides?
The gray market, also written grey market, is the trade in vials of semaglutide, tirzepatide, retatrutide and similar compounds sold online without a prescription, labeled "research use only" or "not for human consumption."
The buyer is not a patient in any formal sense. No provider reviews their health history, and no licensed pharmacy fills or checks the order. The product usually arrives as a powder the buyer mixes and doses themselves. Purity and contents are asserted by the seller, and nothing in the transaction verifies those claims the way a prescription filled by a licensed dispensing pharmacy would. A buyer can pay a commercial lab to test a vial after the fact, which is separate, costs money, and only describes the lot that was sent in.
The FDA has said plainly that it warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were falsely labeled "for research purposes" or "not for human consumption." Its advice to patients is to obtain a prescription from their doctor and fill it at a state-licensed pharmacy. Since September 2025 it has also run a Green List import alert: GLP-1 active pharmaceutical ingredients may enter the country from facilities it has inspected or evaluated, and ingredients from other sources are subject to detention without physical examination.
What are the three ways to get a GLP-1, and what does each cost?
The tiers differ on who decides the dose, who dispenses the drug, what oversight applies, and who is accountable if something goes wrong. Price is one row, and the one most often quoted alone.
| What differs | FDA-approved brand-name | Compounded, by prescription | Research-use peptide |
|---|---|---|---|
| Examples | Wegovy, Zepbound, Foundayo | Compounded semaglutide or tirzepatide | Vials labeled "research use only" |
| FDA approval | Approved as a finished drug after FDA review of safety and efficacy | Not FDA-approved. FDA does not verify safety, effectiveness or quality before marketing | Not approved. FDA has cited sellers for marketing unapproved new drugs |
| Who decides the dose | Licensed provider | Licensed provider | The buyer |
| Who dispenses it | NovoCare Pharmacy, or a licensed dispensing pharmacy through LillyDirect | State-licensed U.S. compounding pharmacy | Online seller, not dispensed against a prescription by a licensed pharmacy |
| CGMP manufacturing standard | Required | Not required for a 503A pharmacy compounding for an individual patient | Not applicable, no pharmacy in the chain |
| Oversight | FDA approval plus state pharmacy licensure | State board of pharmacy licensure, FDA surveillance and for-cause inspection | No prescription requirement and no pharmacy licensure |
| Accountability if something goes wrong | Prescriber, pharmacy and manufacturer of record | Prescriber and pharmacy of record | No prescriber or dispensing pharmacy of record |
| Cost in 2026 | Medication paid separately at the manufacturer's self-pay price. Lowest advertised entry points are $149/mo for the Wegovy pill at 1.5 mg and for Foundayo at its starting dose; Wegovy injection and Zepbound start higher, and conditions apply to each, detailed below. Plus a $99/mo Forva Membership; the membership does not include medication | $139 to $199 every 4 weeks for semaglutide and $239 to $299 for tirzepatide, medication included if prescribed. The lowest figures are 48-week prepaid plans, $1,668 and $2,868 at checkout | Usually the cheapest of the three, with vials commonly advertised under $60 a month. The advertised price is not reliably what a buyer receives: in the one published survey of this market, three of six paid test orders were never delivered at all |
Compounded drug products are not FDA-approved, and the FDA does not evaluate their safety, effectiveness, or quality.
Research-use vials are the cheapest of the three, often by a wide margin. That is the honest starting point. The useful question is what the difference in price buys, and the rows above the cost row are the answer.
Forva's compounded plans bill every 4 weeks, 13 cycles a year rather than 12 calendar months, so $139 every 4 weeks is about $151 per calendar month. Manufacturer prices are quoted per fill, and Lilly defines a one-month supply as 28 days. Those figures are current as of September 2026 and are set by the manufacturer, who can change them.
Every price on this page is cash pay. Forva does not bill, process or accept insurance on either path, and the brand-name figures quoted here are the manufacturers' self-pay prices. The manufacturer's pharmacy does not bill insurance for these products, so that price is what you pay regardless of your coverage.
Why are research peptides labeled "not for human consumption"?
Because in the cases the FDA has acted on, that labeling conflicted with other evidence about what the seller expected the buyer to do with the product.
In warning letters dated March 31, 2026, the FDA told two peptide sellers that evidence from their websites established the products were intended to be drugs for human use, despite labeling that said research use only and not for human consumption. In one, that evidence included product copy about appetite suppression, glucose handling and decreases in body weight. In the other, the FDA pointed to a reconstitution kit containing bacteriostatic water and a syringe, reasoning that the firm intended the water to be used in combination for injection. Both firms' products were cited as unapproved new drugs.
Enforcement in those letters is directed at the sellers, not at the people buying from them. Those are two specific cases and they do not establish a motive for every seller who uses this labeling. What the labeling does not do, in those cases or any other, is make the product reviewed, approved or backed by anyone.
What has independent testing found inside gray market vials?
Peer-reviewed testing has found real and serious defects. In one published study, investigators identified 59 illegal online pharmacies from more than 1,000 search links and attempted six test purchases. Three vials of semaglutide arrived. The other three, for prefilled pens, were paid for and never delivered.
Measured purity in those three vials was 7.70%, 8.97% and 14.37% against a labeled claim of at least 99%, and semaglutide content exceeded the labeled amount by 28.56% to 38.69%. Endotoxin was detected in all three. Those findings are not in conflict: purity is the share of a vial's material that is actually semaglutide, and content is the milligram amount against the label. A buyer measuring out a dose knows neither number. The researchers noted the samples were free of viable microorganisms at the time of testing.
Separately, a commercial testing service that analyzes vials consumers send in has reported that almost 30% of its samples were mislabeled, underdosed, overdosed, or contaminated with toxins or bacteria. That result has not been peer-reviewed, no sample count has been published, and the sample selects itself, since these were vials people already had reason to doubt. So it documents defects among the vials submitted to that one service, and nothing reliable can be concluded from it about how common defects are across the wider market. Read the other way, it also means most vials tested were not flagged for those four problems, which is not the same as meeting a pharmaceutical standard. A buyer cannot tell by looking which vial they have, and a lot that tests clean says nothing about the next one.
How well do people do when they mix and dose a research vial themselves?
Poorly on average, in the one published study that measured it. Researchers asked 20 adults to prepare and self-administer gray market semaglutide using only information they could look up online, scored them against 34 assessed steps, and recorded a mean of 15 of the 34 completed correctly, or 44%. The errors they found were the kind that could result in incorrect dosing, needle sticks or infections. Their conclusion was that untrained adults without experience injecting medications could be at high risk of adverse events when they self-administer these products using only internet information.
This is the part no laboratory result addresses. A test describes the powder. It says nothing about the dilution someone calculates at a kitchen table or the injection itself. That is also why this article does not name sellers or explain how to prepare or dose a research vial.
Is compounded medication FDA-approved?
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved, and the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
Compounded semaglutide is not Wegovy, is not a generic version of Wegovy, and should not be presented as an FDA-approved equivalent. The same is true of compounded tirzepatide and Zepbound. Clinical evidence and FDA approvals that belong to a brand-name product apply to that product, not to a compounded medication. The FDA has warned consumers to be cautious of telehealth sellers that claim compounded medication is the same as an FDA-approved drug, and that warning is worth applying to pages like this one.
So the tiers are genuinely three. Compounded medication sits between the other two: prescribed by a provider and dispensed by a state-licensed pharmacy, which a research vial is not, and not FDA-approved, which a brand-name medication is. Forva compares each pair in compounded semaglutide vs Wegovy and compounded tirzepatide vs Zepbound.
What does a provider-led plan buy you?
A licensed provider who reviews your health history and decides whether a GLP-1 is appropriate at all, which medication, and at what dose. A state-licensed pharmacy that prepares and dispenses it against a prescription written for you, under state board of pharmacy licensure and subject to FDA surveillance and for-cause inspection.
The difference is structural rather than chemical, and that distinction is deliberate. This article makes no claim that one vial is purer than another, because that is not something a company selling the product can prove to you. What it can point to is the chain: a prescriber of record, a pharmacy of record, and somewhere to turn if you react badly. Pharmacy researchers reviewing this market made a related point: avoiding prescribers makes it hard to prevent drug interactions or monitor a patient properly.
One thing a compounded prescription does not add is a CGMP manufacturing standard. Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements. Drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A, the kind Forva's compounded plans use, are not.
Can you get FDA-approved brand-name medication through Forva?
Yes. If a licensed Forva provider determines that an FDA-approved brand-name medication is medically appropriate, the provider can prescribe Wegovy, as a pen or a pill, Zepbound or Foundayo. The prescription goes to the manufacturer's direct pharmacy channel: NovoCare Pharmacy for Novo Nordisk products, or LillyDirect for Lilly products. LillyDirect is Lilly's direct-to-patient service rather than a pharmacy Lilly operates itself, and it routes prescriptions to licensed third-party dispensing pharmacies, currently including Amazon Pharmacy, Gifthealth, Fuze Health and Walmart Pharmacy. Either way you are billed directly at the manufacturer's self-pay price and the medication ships to you. Forva adds no markup and cannot track the shipment.
Forva charges a $99 per month membership covering the provider review, sending the prescription, dose changes and refills, and ongoing care. The membership does not include medication. It is charged at checkout, renews monthly until you cancel, and is refunded in full if your provider does not prescribe.
As of September 2026, Novo Nordisk advertises Wegovy injection at $199 per month for the first 2 fills on starting doses for new patients through December 31, 2026, then $349 for standard pen doses and $399 for the 7.2 mg dose. It advertises the Wegovy pill from $149 for 1.5 mg up to $299 at the highest doses. Lilly advertises Zepbound at $299 for 2.5 mg, $399 for 5 mg and $449 for higher doses on its self-pay program, which requires each refill within 45 days of the previous delivery. Outside that window, Lilly's regular prices of $499 for 7.5 mg and $699 for 10 mg and above apply. Foundayo, Lilly's oral option, starts at $149. These are self-pay prices, set by the manufacturer and subject to change. Novo Nordisk describes its self-pay program as an option for people who do not have insurance or whose benefits do not cover the medicine. Forva does not bill or accept insurance on either path. Neither does the manufacturer's pharmacy for the products prescribed here, so brand-name is self-pay too. Manufacturer savings offers exist separately and have their own eligibility rules.
What is the cheapest legitimate way to get a GLP-1 right now?
A provider-supervised compounded semaglutide plan, at $139 every 4 weeks, about $151 per calendar month, on Forva's 48-week prepaid plan with $1,668 charged at checkout, if a licensed provider prescribes it. Compounded drug products are not FDA-approved, and the FDA does not evaluate their safety, effectiveness, or quality.
Compounded semaglutide runs $199 every 4 weeks month to month. Compounded tirzepatide runs $299 every 4 weeks, down to $239 on the 48-week prepaid plan with $2,868 at checkout. These prices include the provider review, the medication if prescribed, supplies, shipping and ongoing support, with no separate membership fee. Whether a price goes up with your dose is a separate question; Forva's compounded plans cost the same at every dose your provider prescribes, as covered in does GLP-1 pricing go up with your dose.
Prepaid plans are subscriptions. A prepaid term covers that term, then continues at the committed rate until you cancel. The plans are self-pay, insurance is not needed or accepted, and Forva accepts FSA and HSA cards, though whether a purchase counts as a qualified medical expense is determined by your plan administrator. Forva's guide to using an HSA or FSA for GLP-1 treatment covers the details.
The legitimate floor, then, is not the brand-name price people assume. These are not equivalent products, and price is only one input. A licensed provider decides what is appropriate. Results vary.
How should you choose between research peptides, compounded and brand-name GLP-1?
Start with what you want, then price it. If you want a medication the FDA has reviewed for safety and efficacy, only the brand-name path offers it, at the $99 monthly membership plus the manufacturer's self-pay price. If you are paying out of pocket and want a predictable bundled cost with a prescriber and a licensed pharmacy in the chain, a compounded plan may fit, understanding that it is not FDA-approved.
If price is the only thing pushing you toward a research vial, the honest comparison is not a cheap vial against the brand-name price people assume. It is a cheap vial against a provider-supervised compounded plan that can work out to $139 every 4 weeks on the 48-week prepaid plan, $1,668 at checkout, if a provider prescribes it, where a licensed provider picked the dose and a state-licensed pharmacy prepared and dispensed it.
Forva does not guarantee that any particular medication will be prescribed. A licensed provider reviews your online medical intake and decides. On a compounded plan, you pay at checkout, and if treatment is not appropriate, no medication is sent and you're refunded in full. On the brand-name path the $99 membership is refunded in full if your provider does not prescribe. Results vary.
You can review Forva's weight-loss treatment options or start the online evaluation. If you're weighing providers, Forva's checklist on how to tell if an online GLP-1 provider is legitimate covers what to verify.
GLP-1 medications can cause side effects, most commonly nausea, vomiting, diarrhea and constipation, and carry serious risks. Labeling for FDA-approved semaglutide and tirzepatide products includes a boxed warning about thyroid C-cell tumors. Your provider reviews these risks before prescribing.
Wegovy is a registered trademark of Novo Nordisk A/S. Zepbound and Foundayo are trademarks of Eli Lilly and Company. Forva Health is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.
This article is for general information and is not medical advice. Eligibility and treatment decisions are made by a licensed provider.